1K9 Stock Overview Engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Price History & Performance
Summary of share price highs, lows and changes for CareDx Historical stock prices Current Share Price US$23.10 52 Week High US$31.00 52 Week Low US$6.99 Beta 1.86 1 Month Change 1.99% 3 Month Change -16.40% 1 Year Change 126.47% 3 Year Change -32.85% 5 Year Change 11.59% Change since IPO 240.21%
Recent News & Updates
Third quarter 2024 earnings released: US$0.14 loss per share (vs US$0.43 loss in 3Q 2023) Nov 05
Forecast to breakeven in 2026 Nov 05
Caredx, Inc Raises Revenue Guidance for the Full Year 2024 Nov 05
CareDx, Inc to Report Q3, 2024 Results on Nov 04, 2024 Oct 15
CareDx, Inc Appoints Jing Huang as Chief Data and Artificial Intelligence (AI) Officer Oct 09
CareDx, Inc Appoints Keith Kennedy as Chief Operating Officer Sep 12 See more updates
Third quarter 2024 earnings released: US$0.14 loss per share (vs US$0.43 loss in 3Q 2023) Nov 05
Forecast to breakeven in 2026 Nov 05
Caredx, Inc Raises Revenue Guidance for the Full Year 2024 Nov 05
CareDx, Inc to Report Q3, 2024 Results on Nov 04, 2024 Oct 15
CareDx, Inc Appoints Jing Huang as Chief Data and Artificial Intelligence (AI) Officer Oct 09
CareDx, Inc Appoints Keith Kennedy as Chief Operating Officer Sep 12
President of Patient & Testing Services recently sold €1.0m worth of stock Aug 23
Second quarter 2024 earnings released: US$0.027 loss per share (vs US$0.46 loss in 2Q 2023) Aug 01
CareDx, Inc Revises Earnings Guidance for the Full Year 2024 Aug 01
CareDx, Inc to Report Q2, 2024 Results on Jul 31, 2024 Jul 16
CareDx, Inc Announces New Data to Be Presented At the 2024 American Transplant Congress May 31
Study Shows CareDx, Inc.’s HeartCare Outperforms dd-cfDNA Alone in Identifying Rejection and Patients Experienced Excellent Outcomes with Fewer Biopsies May 18
First quarter 2024 earnings released: US$0.32 loss per share (vs US$0.44 loss in 1Q 2023) May 10 CareDx, Inc, Annual General Meeting, Jun 13, 2024 CareDx, Inc Appoints John W. Hanna as Chief Executive Officer
CareDx, Inc Appoints Bryan Riggsbee to Its Board of Directors Mar 12
CareDx, Inc Provides Revenue Guidance for the Full Year of 2024 Feb 29
Full year 2023 earnings released: US$3.54 loss per share (vs US$1.44 loss in FY 2022) Feb 29 CareDx, Inc to Report Q4, 2023 Results on Feb 28, 2024
Jury Rules in Favor of Natera, Inc in Patent Infringement Lawsuit Against CareDx, Inc Jan 29 CareDx, Inc Provides Earnings Guidance for Fourth Quarter Ended December 31, 2023
Delaware Court Denies CareDx’s Motion for Summary Judgment on Two Natera Patents Dec 12
CareDx, Inc to Report Q3, 2023 Results on Nov 08, 2023 Nov 03 CareDx, Inc Announces Resignation of Reginald Seeto as Chief Executive Officer
CareDx Issues Statement on Supreme Court Decision Regarding Stanford-Licensed Patents Oct 05
CareDx, Inc Announces Executive Changes Sep 27 SEC Concludes Investigation as to CareDx and Does Not Intend to Recommend an Enforcement Action Sep 26
New major risk - Revenue and earnings growth Aug 10
Second quarter 2023 earnings released: US$0.46 loss per share (vs US$0.41 loss in 2Q 2022) Aug 09
CareDx, Inc. Provides Revenue Guidance for the Full Year 2023 Aug 09
CareDx, Inc to Report Q2, 2023 Results on Aug 08, 2023 Aug 04
CareDx, Inc. Announces Medicare Coverage for HeartCare Aug 03
CareDx, Inc (NasdaqGM:CDNA) acquired MediGO, Inc. Jul 26
CareDx’s AlloSure Lung dd-cfDNA Testing Service Receives Medicare Coverage for Lung Transplant Rejection Monitoring Jul 12
New major risk - Share price stability Jul 11
First quarter 2023 earnings released: US$0.44 loss per share (vs US$0.37 loss in 1Q 2022) May 11
CareDx, Inc to Report Q1, 2023 Results on May 10, 2023 May 09
Full year 2022 earnings released: US$1.44 loss per share (vs US$0.59 loss in FY 2021) Mar 01
CareDx, Inc. Showcases Latest Advancements in Cellular Transplant and Therapy Including Specialized Digital Health Solutions At the 2023 Tandem Meetings Feb 17
CareDx, Inc Provides Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2022 Jan 10
CareDx, Inc (NasdaqGM:CDNA) announces an Equity Buyback for $50 million worth of its shares. Dec 07
CareDx, Inc Announces the Results of A New Study Published in Transplantation Direct Dec 02
CareDx, Inc Announces Resignation of Ralph Snyderman as Director, Effective from December 31, 2022 Nov 24
Third quarter 2022 earnings released: US$0.32 loss per share (vs US$0.23 loss in 3Q 2021) Nov 05
Caredx, Inc., Revises Revenue Guidance for the Full Year 2022 Nov 04
Independent Longitudinal Study Finds Caredx’S Allosure Detects Early Signs of Rejection in Pediatric Kidney Transplant Patients Nov 02
CareDx, Inc to Report Q3, 2022 Results on Nov 03, 2022 Oct 27
Caredx, Inc Announces Transplant Patients Experience Less Pain and Fewer Adverse Events with Caredx Non-Invasive Testing Solutions Sep 28 CareDx, Inc Announces Executive Changes
CareDx, Inc Announces Resignation of Sasha King as Chief Marketing Officer Sep 02
Independent Director recently sold €60k worth of stock Aug 13
CareDx, Inc Revises Revenue Guidance for the Full Year 2022 Aug 06
Second quarter 2022 earnings released: US$0.41 loss per share (vs US$0.037 loss in 2Q 2021) Aug 05
CareDx Launches Personalized AlloHome Patient Monitoring Solution to Augment Pre- and Post-Transplant Care Aug 03
CareDx, Inc to Report Q2, 2022 Results on Aug 04, 2022 Jul 29
Kessler Topaz Meltzer & Check, LLP Announces Investor Securities Fraud Class Action Lawsuit Filed Against Caredx, Inc Jun 25 Saxena White P.A. Files New Securities Fraud Class Action Against CareDx, Inc
Natera Drops One of Their Two Patents Originally Asserted Against CareDx, Inc May 19
Independent Director recently sold €113k worth of stock May 15 CareDx, Inc Provides Revenue Guidance for the Full Year 2022
First quarter 2022 earnings released: US$0.37 loss per share (vs US$0.013 loss in 1Q 2021) May 07
CareDx, Inc, Annual General Meeting, Jun 15, 2022 May 03
Caredx Demonstrates Potential of Alloheme and Allocell for Allogeneic Cell Transplant and Therapy Monitoring Apr 23
Independent Director recently sold €871k worth of stock Mar 08
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Feb 26 CareDx, Inc Provides Revenue Guidance for the Year 2022
CareDx, Inc to Report Q4, 2021 Results on Feb 24, 2022 Feb 18
Forecast to breakeven in 2024 Jan 19
CareDx, Inc. Announces the Publication of Results from A Large, Multicenter Prospective Study Jan 13
Caredx, Inc Provides Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2021 Jan 12
Forecast to breakeven in 2024 Jan 11
Caredx, Inc Announces the Results of Study Led by the National Institutes of Health Jan 09
CareDx, Inc Successfully Completes CLIA Validation of Allomap Kidney in Preparation for Commercial Launch Jan 07
CareDx, Inc (NasdaqGM:CDNA) acquired The Transplant Pharmacy. Jan 06
CareDx, Inc Enrolls First Patient in LungCare Registry Study to Measure Impact of Multimodality Assessment on Lung Transplant Patient Outcomes Dec 17
Chief Financial Officer recently bought €189k worth of stock Dec 01
Third quarter 2021 earnings released: US$0.23 loss per share (vs US$0.057 loss in 3Q 2020) Oct 29
CareDx, Inc. to Present Six Abstracts on AlloSeq cfDNA and launch of AlloSeq cfDNA Research Service at European Society of Organ Transplantation (ESOT) 2021 conference Aug 27
Second quarter 2021 earnings released: US$0.037 loss per share (vs US$0.15 loss in 2Q 2020) Jul 31
Forecast breakeven pushed back to 2023 Jul 31
CareDx, Inc.Transplant Patient App, Allocare, Expands Access to the Majority of Transplant Patients Jul 03
CareDx, Inc (NasdaqGM:CDNA) acquired Transplant Hero LLC. Jun 09
CareDx, Inc. Enrolls the First Patient in the Molecular Assessment and Profiling of Liver Transplant Recipients (MAPLE) Study At Mount Sinai Hospital in New York Jun 02
Independent Director recently sold €618k worth of stock May 25
Independent Director recently sold €522k worth of stock May 15
First quarter 2021 earnings released: US$0.013 loss per share (vs US$0.14 loss in 1Q 2020) May 07 Shareholder Returns 1K9 DE Biotechs DE Market 7D 11.3% 6.5% 1.3% 1Y 126.5% -1.9% 9.0%
See full shareholder returns
Return vs Market: 1K9 exceeded the German Market which returned 10.1% over the past year.
Price Volatility Is 1K9's price volatile compared to industry and market? 1K9 volatility 1K9 Average Weekly Movement 9.4% Biotechs Industry Average Movement 7.3% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.6% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 1K9's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 1K9's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company Founded Employees CEO Website 1998 639 John Hanna caredx.com
CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software.
Show more CareDx, Inc Fundamentals Summary How do CareDx's earnings and revenue compare to its market cap? 1K9 fundamental statistics Market cap €1.26b Earnings (TTM ) -€140.13m Revenue (TTM ) €305.30m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 1K9 income statement (TTM ) Revenue US$312.78m Cost of Revenue US$107.07m Gross Profit US$205.71m Other Expenses US$349.27m Earnings -US$143.56m
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/10 03:28 End of Day Share Price 2025/01/10 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources CareDx, Inc is covered by 15 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Mark Massaro BTIG William Bonello Craig-Hallum Capital Group LLC Matthew Sykes Goldman Sachs
Show 12 more analysts 
